10X Genomics Inc

10x Genomics reported second-quarter revenue of $151 million, boosted by a $1.6 million settlement payment from Takara, while booked orders for its new Atera instrument platform already exceeded the roughly 40 units planned for all of 2026. Excluding the settlement, revenue grew just 3% year-over-year to $149.4 million, with consumables up 7% and spatial consumables climbing 16% on Xenium strength. Total instrument revenue fell 47% as customers delayed purchases of older systems, and management guided for a sequential revenue step down in the third quarter before a fourth-quarter jump. The company raised full-year revenue guidance to $610 million to $630 million, and cash and marketable securities rose to $552 million. 10x also acquired Proteintech Genomics and announced research partnerships with Cleveland Clinic and Lausanne University Hospital.

10x Genomics reported a second-quarter 2026 loss of 14 cents per share, beating the Zacks Consensus Estimate of a loss of 23 cents by 38.1%. Revenues of $151 million declined 12.6% year over year but surpassed the consensus of $146.9 million by 2.8%, while excluding non-recurring patent litigation settlement revenues in both periods, revenues increased 3%. The company raised its 2026 revenue guidance to $610 million to $630 million from the prior range of $600 million to $625 million, citing first-half performance and $1.6 million of settlement revenue recognized in the quarter. Gross margin expanded 200 basis points to 74%, driven by lower manufacturing costs including $2.6 million of tariff refunds, though the company swung to an operating loss of $19.6 million from an operating income of $30.1 million a year ago. Management noted strong customer response for the Atera platform, with booked orders already well above the roughly 40 instruments previously expected for 2026, and expects a significant sequential revenue increase in the fourth quarter as Atera shipments begin contributing more meaningfully.

Several biotech stocks reached 52-week highs on July 14, 2026, driven by positive clinical data and new program launches. Hemab Therapeutics hit $42.03 after reporting encouraging Phase 2 results for its Von Willebrand's disease candidate HMB-002 and unveiling a new drug candidate, HMB-003, for heavy menstrual bleeding. Alamar Biosciences touched $29.43 following a partnership with U.S. research universities to launch a national proteomics initiative using its NULISAseq Neuro 220 panel for Alzheimer's biomarker discovery. Progyny rose over 4% to $32, with the company projecting full-year 2026 revenue between $1.365 billion and $1.405 billion, a 5.9% to 9% increase. 10x Genomics closed at a 52-week high of $43.98 after recent collaborations, including a bladder cancer diagnostic project with Cleveland Clinic, and expects 2026 revenue of $600 million to $625 million. Viemed Healthcare peaked at $12.61, forecasting net revenues of $312 million to $320 million for 2026.

Roche announced the launch of AXELIOS 1, a next-generation sequencing platform powered by its proprietary sequencing by expansion technology. The platform delivers a unique combination of accuracy, speed, scalability and cost efficiency, enabling same-day whole-genome sequencing in research workflows. AXELIOS 1 is designed for flexibility, allowing laboratories of all sizes to handle everything from small-scale studies to large genomic projects on a single instrument. Roche highlighted collaborations with institutions such as Hartwig Medical Foundation and Broad Clinical Labs, as well as partnerships with 10x Genomics and Google DeepVariant, to support library preparation and analysis. The sequencing market is valued at 7.3 billion dollars and projected to grow at double-digit rates in the coming years.

10x Genomics has entered into a multi-year research collaboration with the Cleveland Clinic to advance novel diagnostic applications for bladder cancer. The study will use the company's Flex Apex and Xenium platforms, with potential expansion to the recently launched Atera platform, to identify biomarkers that may predict patient response to antibody-drug conjugates and immunotherapies. The research will integrate single-cell transcriptomic profiling with spatial gene expression and protein measurements to generate a comprehensive view of tumor biology and the tumor microenvironment. The collaboration is expected to generate a rich multimodal dataset linking molecular insights with clinical outcomes, supporting the development of next-generation precision oncology diagnostics. Shares of 10x Genomics have traded flat since the announcement, though the stock has surged 113.1% year-to-date, compared with a 20.1% decline for the industry and an 8.5% increase for the S&P 500.